1 / 42

SMC Evaluation Programme

SMC Evaluation Programme. Overview. Context Evaluation Programme Stakeholders SMC advice Conclusions. Context. SMC established October 2001 SMC first advice April 2002 Remit

brendan-hopper
Download Presentation

SMC Evaluation Programme

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SMC Evaluation Programme

  2. Overview • Context • Evaluation Programme • Stakeholders • SMC advice • Conclusions

  3. Context • SMC established October 2001 • SMC first advice April 2002 Remit To provide advice to NHS boards and their ADTCs across Scotland about the status of all newly licensed medicines, all new formulations of existing medicines and new indications for established products

  4. Assessment process Patient group Pharmacy assessment Team NDC SMC Proforma Health Economics group Company response Submitted by company Critical Appraisal of submission Scientific Advisory Committee Advice in context of NHS Scotland

  5. Evaluation Programme • Stakeholders • SMC advice

  6. Programme Delivery • Structure • Project Team • Management Group • Reference Group • SMC Executive Team • Timescale • 2 year programme (April 06 - March 08)

  7. Stakeholders

  8. Stakeholders – methods 1Impact on ADTCs role and function • 2000 • 2002 • 2003/4 • 2006/7 Review of Public information • Workshop June 2007 ADTCs n~ 60 + +

  9. Stakeholders – methods 2Engagement with stakeholders Public Partners* Postal questionnaires and interviews (n=154) Pharmaceutical Industry Workshop (n~100) ADTCs Workshop (n~60) + + * ScotCen – Scottish Centre for Social Research

  10. Stakeholders - Key FindingsImpact on ADTCs’ role and function

  11. Key FindingsEngagement with Stakeholders

  12. SMC Advice

  13. Sampling Frame

  14. SMC Advice – method 1 Medicine Profiles ( n=74) • Not Recommended - 20/57 (35%) • Accepted / Restricted – 54/149 (36%)

  15. SMC Advice – method 2 • Case study – Etanercept • Medicine use in psoriatic arthritis • Implementation of SMC Etanercept Protocol (Aug 2006) • Budget Impact • Compare estimate and actual spend (n=28) • Focus group to understand how NHS boards use this information

  16. SMC Advice – Key FindingsNot Recommended advice (n=20) • 65% of advice issued within 6months of medicine launch date • Use before SMC advice (n=20) • £1.4m ( context - £3.7billion) • Use after SMC advice 2005/6 (n=10) • £1m ( 0.1% of drugs bill )

  17. SMC Advice - Key FindingsSMC not recommended advice (n=20)

  18. Limited use relative to alternative treatments

  19. Variation in advice issued by national bodies to NHS boards and clinicians

  20. Lack of engagement of relevant clinical experts in early stages of SMC

  21. SMC Advice - Key FindingsSMC accepted/restricted advice (n=54) • 81% of advice issued within 6 months • Use before SMC advice ( n=41) • £1m (context £3.7billion) • Insufficient robust data for hospital medicines

  22. updateSMC Advice - Key FindingsSMC accepted/restricted advice (n=54)

  23. Comparison of hospital and industry data

  24. SMC Advice – Case Study

  25. SMC Advice - Key FindingsEtanercept Table 1: SMC etanercept protocol – Adherence of NHS boards in Scotland at August 2006

  26. SMC advice - Key Findings Budget Impact • Reliability of budget impact estimates • Unable to meaningfully compare data due to series of factors Experience of NHS Boards’ use of information • Budget information valued by NHS Boards for local planning • Further clarity and definition required to improve quality

  27. Conclusions - Successes • ADTCs have adapted and evolved in response to SMC • SMC has good engagement with ADTCs and Pharmaceutical Industry • Budget impact information is valued by NHS boards

  28. Conclusions – Challenges • Effective engagement with public partners remains a challenge • Monitoring use of medicines is limited by availability of robust hospital medicines data and lack of patient level data

  29. Conclusion – Future Direction • Actions based on the factors identified which help to explain medicine use • Development of a more consistent approach to budget impact estimates • Actions based on findings from public partners • Continued development of effective methodologies to assess the contribution of HTA organisations to patient care

  30. Acknowledgements The project team Marion Bennie Laura McIver Sharon Hems Bill Ramsay Samuel Oduro Vicky Cairns Corri Black Joy Nicholson Rupert Payne

  31. Acknowledgements • SMC Evaluation Reference and Management Groups • SMC (User Group / PAPIG) • SMC (Economic / Admin / Exec Team) • ADTCs and clinical networks • ABPI • Information Services Division staff, NSS • ScotCen / Scott Hill • Sue Hewitt • NHS QIS Comms team

More Related